{
    "clinical_study": {
        "@rank": "73995", 
        "arm_group": {
            "arm_group_label": "XELOX", 
            "arm_group_type": "Experimental", 
            "description": "XELOX: Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:\nCapecitabine 1000 mg/m2 \uff0corally taken 30 minutes after meal, bid \uff0c d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin\uff1a130mg/m2\uff0c iv infusion over 2h\uff0cd1,every 3 weeks"
        }, 
        "brief_summary": {
            "textblock": "Gastric cancer with para-aortic lymph node (PAN) involvement is regarded as advanced\n      disease, and only chemotherapy is recommended from the guidelines. In unresectable cases,\n      neoadjuvant chemotherapy could prolong survival if conversion to resectability could be\n      achieved."
        }, 
        "brief_title": "Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Advanced Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Gastric or gastroesophageal adenocarcinoma proven histologically .\n\n          2. Has para-aortic lymph node metastasis(PAN was defined as nodes in the region between\n             the upper margin of the celiac artery and the upper border of the inferior mesenteric\n             artery (stations no. 16a2/16b1))\n\n          3. Eastern Cooperative Oncology Group performance status of 0 to 1.\n\n          4. Life expectancy \u226512 weeks.\n\n          5. Adequate hematological function: Neutrophil count \u2265 1.5 \u00d7 109/L, Platelets \u2265 100 \u00d7\n             109/L and Hemoglobin \u22659 g/dL (may be transfused to maintain or exceed this level).\n\n             Adequate liver function: Total bilirubin \u2264 1.5 \u00d7 upper limit of normal (ULN); AST\n             (SGOT) and ALT (SGPT) < 2.5 \u00d7 ULN , ALP \u2264 2.5 \u00d7 upper limit of normal (ULN); ALB\n             \u226530g/L\u3002 Adequate renal function: Serum creatinine \u2264 1.25 x ULN, and creatinine\n             clearance \u2265 60 ml/min.\n\n          6. Female subjects should not be pregnant or breast-feeding.\n\n          7. No serious concomitant disease that will threaten the survival of patients to less\n             than 5 years.\n\n        Exclusion Criteria:\n\n          1. Serious concomitant disorders that would compromise the safety of the patient or\n             compromise the patient's ability to complete the study, at the discretion of the\n             investigator.\n\n          2. History of another malignancy in the last 5 years with the exception of the\n             following:\n\n             Any previous palliative, adjuvant or neoadjuvant chemotherapy and/or radiotherapy.\n             Prior treatment for locally advanced or metastatic gastric cancer.\n\n          3. Any other metastatic disease will render patient ineligible according to AJCC staging\n             manual(such as liver\uff0clung\uff0cetc\uff09.\n\n          4. Active infection that in the opinion of the investigator would compromise the\n             patient's ability to tolerate therapy.\n\n          5. Poorly controlled diabetes mellitus with fasting blood sugar > 18 mm. Second primary\n             malignancy that is clinically detectable at the time of consideration for study\n             enrollment.\n\n          6. Unstable, persistent cardiac disease despite medicinal treatment, myocardial\n             infarction within 6 months before the start of the trial\n\n          7. Previous surgery on primary tumour; Prior palliative surgery (open and closure,\n             passage operation)\n\n          8. Any other type of tumour (e.g. leiomyosarcoma, lymphoma) or a secondary malignancy,\n             excepting basal cell skin carcinoma or basal cell carcinoma in situ of the cervix\n             which have already been successfully treated -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02071043", 
            "org_study_id": "ZS-ON-03"
        }, 
        "intervention": [
            {
                "arm_group_label": "XELOX", 
                "description": "Capecitabine 1000 mg/m2 \uff0corally taken 30 minutes after meal, bid \uff0c d 1~14 every 3", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "XELOX", 
                "description": "Oxaliplatin\uff1a130mg/m2\uff0c iv infusion over 2h\uff0cd1,every 3 weeks", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Capecitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "neo-adjuvant chemotherapy", 
            "advanced gastric cancer patients", 
            "para-aortic lymph node metastasis"
        ], 
        "lastchanged_date": "February 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Zhongshan Hospital Affiliated to Fudan University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Medicine-Oncology Derpartment of Zhongshan hospital", 
            "last_name": "Tianshu Liu, Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "China: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "evaluation will be based on tumor assessment with follow-up, including chest and upper-abdominal During preoperative treatment period, CT scan will be performed every 6 -8 weeks (2 cycles after).After surgery, CT scan will be planned every 3 months, brain MRI  and  bone scan (ECT)  will be performed if any suspected symptoms occur.", 
            "measure": "The primary study end point was the response rate of preoperative XELOX followed by surgery in gastric cancer patients with PAN involvement", 
            "safety_issue": "No", 
            "time_frame": "8 Months after the last subject participate in"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02071043"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "be based on tumor assessment with follow-up, including chest and upper-abdominal During preoperative treatment period, CT scan will be performed every 6 -8 weeks (2 cycles after).After surgery, CT scan will be planned every 3 months, brain MRI  and  bone scan (ECT)  will be performed if any suspected symptoms occur.", 
                "measure": "progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "40 Months after the last subject participate in"
            }, 
            {
                "description": "out-patient clinic and telephone visit will be done every 3 months for the first two years, and every 6 months after two years", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years after the last subject participate in"
            }, 
            {
                "description": "Adverse Events will measure in the whole study  according to CTC-AE 4.0", 
                "measure": "Grade 3 or 4 Adverse Events as a Measure of Safety", 
                "safety_issue": "Yes", 
                "time_frame": "1 year after the last subject finish the treatment"
            }
        ], 
        "source": "Shanghai Zhongshan Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Zhongshan Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}